# Belumosudil PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/belumosudil

> The next catalyst for belumosudil, sponsored by Sanofi (SNY), is its topline data readout, Sep to Dec 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | belumosudil |
| Codes | SAR445761 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Lung Transplant Rejection](https://sec-api.dev/indications/lung-transplant-rejection), [Chronic Graft Versus Host Disease](https://sec-api.dev/indications/chronic-graft-versus-host-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Graft Versus Host Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06143891 (A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06143891

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Graft Versus Host Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07116031 (A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07116031

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Graft Versus Host Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07116031 (A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07116031

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Graft Versus Host Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06143891 (A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06143891

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Lung Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06082037 (A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06082037

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Lung Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06082037 (A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06082037

### Sep to Dec 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Graft Versus Host Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07771439 (A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07771439

### September 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Graft Versus Host Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07771439 (A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07771439

Calendar months: [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/belumosudil.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Belumosudil PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/belumosudil

```bibtex
@misc{secapidev_pdufa_belumosudil_20261116,
  title        = {Belumosudil PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/belumosudil}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_belumosudil_20261116","title":"Belumosudil PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/belumosudil","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
